SCHEMBL30228447

SCHEMBL30228447

[2H]C([2H])([2H])N(CCC(=O)O)c1ccc2c(-c3ccccc3C)cc(=O)oc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNA3 P22001 1/20 0.44
▸ IGLV6-57 P01721 3/20 0.44
▸ ALDH1A1 P00352 9/20 0.42
▸ HPGD P15428 7/20 0.42
▸ KDM4E B2RXH2 4/20 0.42
▸ GLA P06280 2/20 0.42
▸ GAA P10253 2/20 0.42
▸ HSD17B10 Q99714 3/20 0.41
▸ KMT2A Q03164 3/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ L3MBTL1 Q9Y468 2/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ CASP1 P29466 1/20 0.40
▸ CASP7 P55210 1/20 0.40
▸ ATM Q13315 1/20 0.40
▸ HIF1A Q16665 1/20 0.40
▸ LMNA P02545 3/20 0.39
▸ HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30228394 0.95 IGLV6-57 (0.41) KCNA3IGLV6-57ALDH1A1HPGDKDM4E
SCHEMBL30228335 0.93 IGLV6-57 (0.49) KCNA3IGLV6-57ALDH1A1HPGDKDM4E
SCHEMBL30228309 0.85 KCNA3 (0.43) KCNA3IGLV6-57ALDH1A1HPGDKDM4E
SCHEMBL30228557 0.84 KCNA3 (0.43) KCNA3IGLV6-57ALDH1A1HPGDKDM4E
SCHEMBL30228602 0.84 KCNA3 (0.43) KCNA3IGLV6-57ALDH1A1HPGDKDM4E
SCHEMBL30227938 0.84 IGLV6-57 (0.51) KCNA3IGLV6-57ALDH1A1HPGDKDM4E
SCHEMBL30228269 0.84 IGLV6-57 (0.46) KCNA3IGLV6-57ALDH1A1HPGDKDM4E
SCHEMBL30228470 0.83 IGLV6-57 (0.48) KCNA3IGLV6-57ALDH1A1HPGDKDM4E
SCHEMBL30228295 0.82 IGLV6-57 (0.49) IGLV6-57ALDH1A1HPGDKDM4EGLA
SCHEMBL30228451 0.81 CA12 (0.56) KCNA3IGLV6-57ALDH1A1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250326732-A1 CHROMEN-2-ONE MODULATORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2025-10-23 — — US disclosed
WO-2023034346-A1 CHROMEN-2-ONE MODULATORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2023-03-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250326732-A1 CHROMEN-2-ONE MODULATORS OF POLRMT POLRMT, TFAM, POLM KCNA3 4258/4885IGLV6-57 4814/4885ALDH1A1 3178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback